article thumbnail

US FDA grants orphan drug status to IN8bio’s INB-400 and INB-410

Pharmaceutical Technology

This marks the first-ever designation for genetically modified gamma-delta T cell therapies. INB-400, an autologous, genetically engineered gamma-delta T cell therapy, is the company’s DeltEx chemotherapy-resistant autologous and allogeneic drug-resistant immunotherapy (DRI) technology.

article thumbnail

Bone Therapeutics inks iPSC related research partnership

BioPharma Reporter

A new deal sees Bone Therapeutics gain access to iPSC derived, genetically engineered MSCs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

This week in drug discovery (5-9 September)

Drug Discovery World

Notably, it was a mixed week for PARP inhibitor olaparib, which was approved by regulator the MHRA for patients with early-stage breast cancer, but rejected by NICE for use on the NHS in metastatic prostate cancer. This week’s top stories: Combination therapy halts lung cancer tumour growth in mice.

Drugs 52
article thumbnail

BE labeling Rule Challenge Largely Fails but Court Takes Issue with Electronic and Text Message Disclosure Options

FDA Law Blog

Plaintiffs challenged the use of the term bioengineered (rather than GMO or genetically engineered), the limitation of the mandatory disclosure being required only if the food contains detectable modified genetic material and the options of using a QR code disclosure or a text message for the disclosure statement.

article thumbnail

Precision Fermentation Study May Revolutionize Food Quality and Sustainability

XTalks

The precision fermentation study highlights how genetically engineered microorganisms can inhibit the growth of foodborne pathogens. Words like “bioengineered” and “genetically modified” often provoke negative reactions. This not only extends the shelf life of foods but also ensures they are safer for consumption.

article thumbnail

South African variant may cut response from Pfizer/BioNTech shot, study finds

pharmaphorum

Researchers from the University of Texas Medical Branch based their findings on lab tests using SARS-CoV-2 coronaviruses that were genetically engineered to have the same mutations as those in the strain that is causing scientists so much concern.

article thumbnail

2nd Macrophage-directed Therapies Summit

pharmaphorum

Some highlights on the 2020 agenda: Nicholas Poirier , Chief Scientific Officer, OSE Immunotherapeutics will explore a novel ‘don’t eat me’ target regulating macrophages phagocytosis and dendritic cell antigen presentation.